The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) showed no difference in ovarian cancer mortality between women screened with CA125 and TVUS and normal clinical care [5]. This evidence concerns the gene MUC16 and ovarian cancer.